PD-L1 expression + HER-2 overexpression

P1, N=27, Recruiting, Institut Paoli-Calmettes | Trial completion date: Feb 2026 --> Mar 2027 | Trial primary completion date: Mar 2025 --> Mar 2027

Complementary platforms including circulating tumour DNA and theranostic agents are also being explored to better guide treatment selection, facilitate non-invasive monitoring and enable early response assessments. In this Review, we summarize the current standard of care for patients with metastatic gastric cancer and also highlight emerging approaches aimed at improving the outcomes in these patients.

Preliminary evidence suggests that T1 and T2 mapping can yield reproducible quantitative metrics, which may offer a means to non-invasively assess HER2 and PD-L1 expression in bladder cancer.

P1/2, N=980, Recruiting, BioNTech SE | N=550 --> 980 | Trial completion date: Feb 2030 --> Oct 2029 | Trial primary completion date: May 2028 --> Feb 2028

We analyze diverse therapeutic payloads, including conventional chemotherapeutics (paclitaxel, doxorubicin, and docetaxel), natural products (curcumin and resveratrol), and molecular therapeutics (siRNAs and CRISPR/Cas9) delivered via albumin nanoplatforms. The clinical evidence supporting nab-paclitaxel in combination with immune checkpoint inhibitors has demonstrated significant improvements in progression-free survival and objective response rates in PD-L1-positive mTNBC patients, whereas real-world studies have confirmed manageable safety profiles...Future directions emphasize the development of multistimuli-responsive albumin nanocarriers, integration with gene editing and immunotherapy, artificial intelligence-guided design optimization, and precision medicine strategies tailored to individual tumor profiles. The convergence of the natural tumor affinity of albumin with advanced nanotechnology holds substantial promise for overcoming drug resistance, enhancing therapeutic specificity, and improving clinical outcomes in TNBC patients, positioning albumin-based nanomedicine as a transformative approach in precision oncology.

These findings are hypothesis generating and provide rationale for future clinical trials of ADCs and immune checkpoint inhibitors in VSCC. Results suggest HPV-independent tumors may be immunogenically active.

From 36 HER2 positive cases, 32(32,5%) were with score 2+, and 4(4,4%) with score 3+. Continued research into molecular mechanisms and biomarkers holds the promise of further improving CRC outcomes through personalized and effective interventions.

These findings support the feasibility and antitumor activity of perioperative chemoimmunotherapy targeting HER2 and PD-1 and warrant further validation in randomized trials. ClinicalTrials.gov registration: NCT05504720 .

Adjuvant therapy with the TCbHP regimen (docetaxel, carboplatin, pertuzumab, and trastuzumab) was initiated, with a total of six cycles planned, followed by maintenance therapy with trastuzumab and pertuzumab (HP) for 1 year. To date, the patient has tolerated the treatment well without evidence of distant recurrence or metastasis. This case underscores the discordance between radiological and pathological findings in breast cancer, highlighting the clinical significance of low TILs and high PD-L1 expression in HER2-positive tumors, and emphasizes the importance of individualized surgical and adjuvant treatment strategies.

P1/2, N=243, Active, not recruiting, AstraZeneca | Trial completion date: Nov 2024 --> Feb 2027

Most EGJ and Barrett's adenocarcinomas may be eligible for molecular targeted therapy. Appropriate patient stratification based on these molecular tests will be important for precision medicine of the EGJ and Barrett's adenocarcinoma.

Once a gastric-type phenotype is confirmed, mutation surrogate immunostains can be used to support a diagnosis of GAS. PD-L1 and HER2 expression is seen in a subset of GAS offering therapeutic options for this aggressive tumor.